|

JSB462 Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: luxdegalutamide

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Novartis Pharmaceuticals3

Indications

  • Cancer3
  • Metastatic Prostate Cancer (mCRPC)1
  • Metastatic Hormone-sensitive Prostate Cancer1
  • Prostatic Cancer, Castration-Resistant1

Other1 trial

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Phase 1

Casa Grande, Arizona1 trial

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Cancer And Blood Spclsts of AZ

Phase 2

La Jolla, California1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

University of California San Diego - Moores Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.